- OTCQB: IZOZF
- CSE: IZO
- FSE: 1R3
Introducing IzoView. Engineered for Today's Challenges and Tomorrow's Care Models.
There’s a gap in breast cancer imaging. We’re here to close it.
IzoView is the first and only dedicated Breast CT platform that's specifically focused on the 50% of women with dense breast tissue, where traditional tools often fail. With true 3D imaging, no compression, and 100x the spatial resolution of MRI, IzoView is purpose-built to detect what others can miss- in a fast and comfortable scan.
Now preparing for a pivotal clinical study, IzoView is positioned to lead a new category in breast imaging.
Get InvolvedThe Result of Decades of Research.
Breast CT technology has been built, tested, and refined in clinical trials for academic research purposes over the last 20 years. Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model.
Read the DataBuilt by Experts. Driven by Purpose.
Izotropic is led by a multidisciplinary team of experts in medical imaging, clinical research, engineering, and commercialization. Together, they are advancing IzoView from proven science to real-world impact.
Meet the TeamJoin Us at the Inflection Point.
The global breast imaging market is projected to reach $8.7 billion by 2030, driven by demand for earlier, more accurate cancer detection. With a first-in-class device and a focused clinical strategy, Izotropic offers a unique opportunity to invest at the forefront of a fast-growing sector.
Learn MoreFeatured News
-
8/5/2025 Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers
